Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

Trial Profile

A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms BREEZE-AD6
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 03 Dec 2018 Planned End Date changed from 10 May 2021 to 19 Jul 2021.
    • 03 Dec 2018 Planned primary completion date changed from 12 Apr 2019 to 14 Oct 2019.
    • 18 Jul 2018 Planned End Date changed from 15 Jan 2021 to 10 May 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top